Exclusive Summary

• Entecavir is a first-line antiviral drug recommended by guidelines with a large global chronic hepatitis B patient base and sustained strong market demand.
• Original patents expired years ago, leading to a mature global generic market with intense competition but vast unmet patient needs, especially in developing countries.
• As a WHO essential medicine, Entecavir offers high cost-effectiveness and accessibility, securing a stable market position in many countries.
• Chinese suppliers, with their large-scale production and cost control advantages, can provide high-quality, competitively priced generic Entecavir.
• Pursuing international GMP certifications and efficient registration processes will facilitate rapid entry into mainstream international and emerging markets.